Micro Interventional Devices
- Company typePrivate
- Founded2010
- HeadquartersNewtown, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Micro Interventional Devices firmographics
Firmographics- Name
- Micro Interventional Devices
- Legal name
- Micro Interventional Devices, Incorporated
- Website
- https://microinterventional.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Micro Interventional Devices industry classification
Industry- Product category
- Structural Heart Repair Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)
- akta.pro secondary industry
- Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems) (HLAHAFAK)
Keywords
Where Micro Interventional Devices is headquartered
LocationHeadquarters
- HQ city
- Newtown
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Micro Interventional Devices business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Sales: MID designs, manufactures and commercializes catheter-based technologies for structural heart disease treatment. As a pre-commercial/early commercial medical device company with products in clinical trials, revenue will come from sales of transcatheter cardiac repair devices and delivery systems to hospitals and cardiac centers following regulatory approvals (CE Mark and FDA).
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Micro Interventional Devices product offering
Product offeringCore offering
Micro Interventional Devices (MID) designs, manufactures and commercializes catheter-based technologies for transcatheter cardiac repair (TCR) of structural heart disease. Its core products are the MIA-T Percutaneous Tricuspid Annuloplasty System and the MIA-M Percutaneous Mitral Annuloplasty System, both built on a proprietary PolyCor anchor platform deployed through a 12F catheter to replicate surgical annuloplasty on a beating heart without cardiopulmonary bypass. The MIA-T system has FDA Breakthrough Device Designation and IDE approval for a US pivotal trial, while European clinical trial data from the STTAR study covers 31 treated patients to date.
Product overview
Micro Interventional Devices (MID) develops a platform of transcatheter cardiac repair (TCR) products that replicate established surgical structural heart repair procedures percutaneously. The core technology is the proprietary PolyCor anchoring system, which serves as the foundation for two main product lines: the MIA-T (for tricuspid valve repair) and MIA-M (for mitral valve repair). Both systems use 12F catheter-based delivery to deploy anchors and proprietary suture locks, enabling structural heart repair while the heart is beating without the need for cardiopulmonary bypass.
Differentiator
Problem solved
Functional benefit
Products and services
- MIA-T Percutaneous Tricuspid Annuloplasty System Percutaneous annuloplasty system for tricuspid valve repair that replicates a surgical annuloplasty procedure on the end of a 12F catheter. Deploys proprietary PolyCor anchors and a proprietary suture lock into the tricuspid annulus in 4/1000ths of a second to reduce annular dimensions and tricuspid regurgitation. Image-guided using fluoroscopy and 2D/3D echocardiography on a beating heart without cardiopulmonary bypass. Intended for patients with tricuspid regurgitation who are ineligible for open-heart surgery. Currently an investigational device.
- MIA-M Percutaneous Mitral Annuloplasty System Percutaneous annuloplasty system for mitral valve repair that places permanent cardiac implants into the mitral annulus for patients with Grade 2 or greater functional mitral regurgitation. Uses a closed-chest, beating-heart, transcatheter technique via transvenous, transseptal approach through the femoral vein. Built on the same PolyCor anchor and 12F catheter platform as MIA-T.
- PolyCor™ Anchors Proprietary ultra-low mass, biocompatible polymeric anchors specifically designed for soft-tissue cardiac applications. Deploy from catheter-based delivery systems in 4/1000ths of a second, create secure purchase in tissue, comply with wall-motion, do not back out, and include radiopaque markers for visibility on imaging. Function as the foundational anchoring component of MID's transcatheter annuloplasty systems.
Quantifiable outcome
- Significant reductions in annular dimensions and tricuspid regurgitation achieved acutely with MIA-T are durable at one-year follow-up
- +2 more outcomes
Companies that use Micro Interventional Devices
Customer profileSegments1 record
Ideal customer profiles1 record
Micro Interventional Devices technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Micro Interventional Devices partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Neovasc, Inc.minorMID reached a settlement agreement with Neovasc, Inc. in February 2019. This was a legal settlement rather than a commercial partnership.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Micro Interventional Devices competitors and assessment
Company assessmentBroad incumbents
- Abbott: Abbott markets the TriClip transcatheter tricuspid repair system (FDA-approved) and the MitraClip system for mitral repair — directly comparable transcatheter valve repair products targeting the same patient populations and delivered via similar percutaneous catheter approaches.
- Edwards Lifesciences: Edwards has the Cardioband tricuspid repair system and the PASCAL mitral repair platform, making it one of the largest and most established incumbents in the percutaneous tricuspid and mitral repair space where MID competes.
- Medtronic: Medtronic is a broad incumbent in structural heart with the Intrepid transcatheter mitral valve replacement program and a large interventional cardiology salesforce, competing for the same hospital budgets and structural heart programs as MID's MIA-T and MIA-M.
- Boston Scientific: Boston Scientific is a broad medtech incumbent that has invested in structural heart programs (including transcatheter mitral investments) and serves the same hospital cardiology and cardiac surgery customers that MID targets with its TCR platform.
Direct peers
- Cardiac Dimensions: Cardiac Dimensions develops the Carillon percutaneous annuloplasty system for functional mitral regurgitation — a near-direct competitor to MID's MIA-M, addressing the same indication via a transcatheter coronary sinus-based annuloplasty approach.
- 4Tech Cardio: 4Tech Cardio is developing transcatheter tricuspid annuloplasty technology (Cardioband predecessor / similar percutaneous annular repair approach), making it a direct competitor in the same MIA-T category with overlapping clinical trial timelines and indications.
- NeoChord: NeoChord develops transcatheter chordal repair technology for mitral regurgitation (DS1000 system via transapical delivery) — a direct peer in the percutaneous mitral repair space targeting the same pathology with a different mechanical approach.
Emerging players
- Ancora Heart: Ancora Heart is developing the AccuCinch transcatheter ventricular repair system for functional mitral regurgitation, an emerging player in the percutaneous mitral repair category with overlapping clinical positioning to MIA-M.
- Cardiovalve: Cardiovalve (acquired by Venus Medtech) is developing a transcatheter tricuspid and mitral valve replacement technology — an emerging player in the structural heart repair category overlapping MID's MIA-T and MIA-M indications.
- Polaris Cardiovascular: Polaris Cardiovascular develops transcatheter tricuspid repair devices, an emerging competitor in the same percutaneous tricuspid annular repair space where MID's MIA-T competes.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Micro Interventional Devices social profiles
Digital presenceMicro Interventional Devices compliance and trust
Trust signalCompliance1 record
Micro Interventional Devices financial estimates
Financial estimateRevenue estimate
Valuation estimate
Micro Interventional Devices leadership team
Management profileNumber of profiles
Profiles6 records
Micro Interventional Devices funding detail
Funding detailFunding overview
Funding rounds5 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Micro Interventional Devices M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Micro Interventional Devices
What does Micro Interventional Devices do?
Micro Interventional Devices (MID) designs, manufactures and commercializes catheter-based technologies for transcatheter cardiac repair (TCR) of structural heart disease. Its core products are the MIA-T Percutaneous Tricuspid Annuloplasty System and the MIA-M Percutaneous Mitral Annuloplasty System, both built on a proprietary PolyCor anchor platform deployed through a 12F catheter to replicate surgical annuloplasty on a beating heart without cardiopulmonary bypass. The MIA-T system has FDA Breakthrough Device Designation and IDE approval for a US pivotal trial, while European clinical trial data from the STTAR study covers 31 treated patients to date.
Is Micro Interventional Devices a public or private company?
Micro Interventional Devices is a private company. It is classified as venture growth investor backed and is currently operating.
When was Micro Interventional Devices founded?
Micro Interventional Devices was founded in 2010. It employs 11 to 50 people.
Where is Micro Interventional Devices based?
Micro Interventional Devices is headquartered in Newtown, United States, in the North America region.
How does Micro Interventional Devices make money?
One revenue line is on record: medical Device Sales.
Who are Micro Interventional Devices's main competitors?
Broad incumbents on record are Abbott, Edwards Lifesciences, Medtronic and Boston Scientific. Direct peers are Cardiac Dimensions, 4Tech Cardio and NeoChord. Emerging players are Ancora Heart, Cardiovalve and Polaris Cardiovascular.
Does Micro Interventional Devices have an API?
No public API is recorded for Micro Interventional Devices.
What industry is Micro Interventional Devices in?
Micro Interventional Devices's product category is Structural Heart Repair Devices. Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair, with a secondary code of HLAHAFAK, Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems). Its NAICS code is 339112 and its SIC code is 3841.